Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Nano-X Imaging Ltd. and Encourages Investors with Losses to Contact the Firm

11/23/2021 | 03:03pm EST

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nano-X Imaging Ltd. (“Nanox” or “the Company”) (NASDAQ: NNOX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The 510(k) application submitted by Nanox for the Nanox.ARC was deficient. Based on this deficiency, the FDA was unlikely to approve the application as submitted. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Nanox, investors suffered damages.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

ę Business Wire 2021
All news about NANO-X IMAGING LTD.
01/18Nano-X Imaging Ltd. Announces It Has Submitted with the Food and Drug Administration Q-..
01/11Nanox Announces Issuance of American Medical Association New Category III CPT« Code for..
01/11Nano-X Imaging Ltd. Announces Issuance of American Medical Association New Category III..
2021USARAD, a Nanox Company, Achieves the Joint Commission Re-Certification
2021Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures..
2021Nano-X Imaging Ltd. Announces Resignation of Jung Ho Park as Member of the Board of Dir..
2021Nanox to Host Virtual Tour of Nanox.ARC in a Clinical Setting at the Radiology Society ..
2021INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against ..
2021INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Nan..
2021Nano-X Imaging's Q3 Adjusted Loss Widens, Operating Expenses Increase
More news
Analyst Recommendations on NANO-X IMAGING LTD.
More recommendations
Financials (USD)
Sales 2021 0,50 M - -
Net income 2021 -63,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,42x
Yield 2021 -
Capitalization 581 M 581 M -
Capi. / Sales 2021 1 163x
Capi. / Sales 2022 97,7x
Nbr of Employees 50
Free-Float -
Duration : Period :
Nano-X Imaging Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANO-X IMAGING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 11,25 $
Average target price 50,50 $
Spread / Average Target 349%
EPS Revisions
Managers and Directors
Ran Poliakine Chairman & Chief Executive Officer
Ran Daniel Chief Financial Officer
Ofir Koren Chief Technology Officer
Uri Shimon Vice President-Information Systems & Technology
James Dara Chief Operating Officer
Sector and Competitors